Zhou Zhanmei, Hu Zheng, Li Mei, Zhu Fengxin, Zhang Hao, Nie Jing, Ai Jun
State Key Laboratory of Organ Failure Research, National Clinical Research Center of Kidney Disease, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, P.R. China.
Tasly R&D Institute, Tianjin, P.R. China.
PLoS One. 2016 Sep 16;11(9):e0162873. doi: 10.1371/journal.pone.0162873. eCollection 2016.
Chronic kidney disease (CKD) is becoming a worldwide problem. However, current treatment options are limited. In the current study we showed that QiShenYiQi (QSYQ), a water-ethanol extract from several Chinese medicines, is a potent inhibitor of renal interstitial fibrosis. QSYQ inhibited transforming growth factor-β1 (TGF-β1)-responsive α-smooth muscle actin (α-SMA), collagen I, and fibronectin up-regulation in obstructive nephropathy and cultured cells. Administration of QSYQ also inhibited the established renal interstitial fibrosis in obstructive nephropathy. Interestingly, QSYQ selectively inhibited TGF-β1-induced β-catenin up-regulation and downstream gene transcription. Taken together, our study suggests that QSYQ selectively inhibits TGF-β1-induced β-catenin up-regulation and might have significant therapeutic potential for the treatment of renal fibrosis.
慢性肾脏病（CKD）正成为一个全球性问题。然而，目前的治疗选择有限。在本研究中，我们表明，芪参益气（QSYQ），一种从多种中药中提取的水-乙醇提取物，是肾间质纤维化的有效抑制剂。QSYQ抑制梗阻性肾病和培养细胞中转化生长因子-β1（TGF-β1）反应性α-平滑肌肌动蛋白（α-SMA）、I型胶原和纤连蛋白的上调。给予QSYQ还可抑制梗阻性肾病中已形成的肾间质纤维化。有趣的是，QSYQ选择性抑制TGF-β1诱导的β-连环蛋白上调和下游基因转录。综上所述，我们的研究表明，QSYQ选择性抑制TGF-β1诱导的β-连环蛋白上调，可能对肾纤维化治疗具有显著的治疗潜力。
